D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in ...
Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...
Okay. Well, thank you, everyone, for joining us. We are here with FDMT. Kristian Humer, CFO; and Chris Simms, CCO and CBO. Maybe you could start with an overview of your directed evolution gene ...
FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting ...
Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...
Ocugen has no product revenue, remains loss-making, and the convertible notes add debt burden and potential share dilution.
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results